J&J MedTech, Qure.ai Launch AI-Driven Lung Cancer Detection Clinics in India

The initiative focuses on establishing AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across key hospitals in the country.

Johnson & Johnson MedTech has partnered with Qure.ai to support the early detection of lung cancer in India. 

As part of a broader strategic collaboration titled Project BreatheEZ, the initiative focuses on establishing AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across key hospitals in the country.

These AI-enabled screening clinics are designed to function as integrated hubs for early detection, triage, and follow-up care in lung cancer, which remains a growing public health burden in India. The first of these clinics has been launched at Thangam Cancer Centre in Namakkal, Tamil Nadu.

As per the agreement, Qure.ai’s artificial intelligence technology will be deployed across 10 hub medical centers and 20 additional spoke sites. This network aims to facilitate the timely identification of lung nodules that may go unnoticed in routine medical imaging.

According to the press release, the burden of cancer in India continues to rise, with projections indicating an increase from 26.7 million DALYs in 2021 to 29.8 million by 2025. The initiative intends to address this growing need through improved detection methods.

Anuj Virmani, MD, India, Johnson & Johnson MedTech, said, “Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, which continues to drive impactful collaborations and integrating our solutions in lung cancer.”

The clinics are expected to be critical in identifying lung cancer at earlier stages, thereby improving patient outcomes. 

The model follows a hub-and-spoke structure, ensuring wider reach and accessibility across regions.